Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jan Brandes

Nashville, TN Medical Doctor

NPI 1093707937 CMS profile 139546

300 20Th Ave N, Suite 106, Nashville, TN 37203

Open in the dashboard

General payments

$555,316

563 records reported · program years 2019–2025

Research payments

$675

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$85,300 paid to institutions, not to them · program years 2019–2021

Through program year 2025, Jan Brandes of Nashville, TN is reported in the CMS Open Payments database as having received $555,316 across 563 general payments and $675 in research payments paid to them. Separately, studies naming them as principal investigator received $85,300 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,090 5
2023 General $21,882 15
2022 General $76,549 52
2021 General $69,057 48
2021 Research $675 1
2020 General $156,554 177
2019 General $230,184 266

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jan Brandes
  • Tennessee median
  • Middle half of Tennessee
  • National median

In program year 2025, general payments to Jan Brandes were reported at $1,090. Among 24,836 Tennessee profiles paid that year, the median was $199 and the middle half received between $54 and $728.

Show as a table
Year Jan Brandes Tennessee median Middle half National median
2019 $230,184 $197 $58–$789 $163
2020 $156,554 $132 $38–$484 $114
2021 $69,057 $145 $39–$541 $132
2022 $76,549 $170 $50–$642 $149
2023 $21,882 $183 $50–$668 $160
2024 $0 $187 $51–$700 $164
2025 $1,090 $199 $54–$728 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Lilly USA, LLC $277,227 307 payments
  2. Amgen Inc. $161,415 153 payments
  3. Lundbeck LLC $41,150 22 payments
  4. Eli Lilly and Company $37,880 25 payments
  5. Teva Pharmaceuticals USA, Inc. $18,996 11 payments
  6. Allergan Inc. $12,478 22 payments
  7. Impel Pharmaceuticals Inc. $3,225 5 payments
  8. AbbVie, Inc. $2,045 3 payments
  9. H. Lundbeck A S $619 1 payment
  10. US WorldMeds, LLC $258 12 payments
  11. Other $24 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $363,918 204 payments
  2. Consulting Fee $105,110 27 payments
  3. Travel and Lodging $46,741 126 payments
  4. Honoraria $27,375 9 payments
  5. Food and Beverage $8,466 190 payments
  6. Education $3,620 5 payments
  7. Grant $85 2 payments
Products named General payments · program years 2019–2025
  1. AIMOVIG $159,885 149 payments
  2. EMGALITY $153,537 156 payments
  3. REYVOW $105,285 72 payments
  4. VYEPTI $19,303 10 payments
  5. UBRELVY $12,420 18 payments
  6. Ajovy Central Nervous System $11,187 6 payments
  7. AJOVY Central Nervous System $3,382 4 payments
  8. Trudhesa $3,188 3 payments
  9. QULIPTA $1,920 2 payments
  10. Xadago $238 11 payments
  11. Other $452 19 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $675 1 payment

Records

564 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record